Diabetes Patents (Class 514/6.9)
-
Publication number: 20110237503Abstract: The present invention is in the field of treatment of diabetes and relates to peptides that exhibit activity for both glucose-dependent insulinotropic peptide receptor (GIP-R) and glucagon-like peptide-1 receptor (GLP-1-R) and are selective over glucagon receptor (Gluc-R). Specifically provided are GIP analogs with amino acid substitutions introduced to modulate activity for both GIP-R and GLP-1-R and maintain selectivity over Gluc-R.Type: ApplicationFiled: March 23, 2011Publication date: September 29, 2011Applicant: ELI LILLY AND COMPANYInventors: Jorge ALSINA-FERNANDEZ, Krister Bengt BOKVIST, Lili GUO, John Philip MAYER
-
Publication number: 20110230398Abstract: Apoliporotein C-II or any active fraction of its amino acid sequence that activates lipoprotein lipase (LPL) in mammals. Increase in activity of LPL can increase expenditure of energy, and therefore an activator of LPL can be an effective agent for the prevention or treatment of obesity or related metabolic disorders, including cardiovascular disease, diabetes and hypertension in mammals including domestic pets and humans. Apolipoprotein C-II or its active fractions can be used as a diet supplement in the form of fortification to a natural product such as milk, cereal, beverage; as a nutritional supplement; or as a therapeutic agent in conventional forms of administration.Type: ApplicationFiled: March 19, 2010Publication date: September 22, 2011Inventor: Surendra K. Gupta
-
Publication number: 20110229525Abstract: Cell penetrating suppressor of cytokine signaling (CP-SOCS) molecules engineered to be resistant to intracellular degradation are discussed. Methods of treating diseases associated with cytokine signaling include one or more CP-SOCS degradation resistant molecules.Type: ApplicationFiled: March 14, 2011Publication date: September 22, 2011Applicant: Vanderbilt UniversityInventors: Jack Jacek Hawiger, Antonio Digiandomenico
-
Publication number: 20110230404Abstract: Methods of increasing the yield in plant expression of recombinant proteins comprising engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive post-translational modifications in plants; and engineering the cloned genes or cDNAs to contain a plant secretory signal sequence that targets the gene products (protein) for secretion. The methods result in increased recombinant glycosylated protein yields. Proteins produced according to these methods are disclosed.Type: ApplicationFiled: January 13, 2011Publication date: September 22, 2011Applicant: OHIO UNIVERSITYInventors: Marcia J. Kieliszewski, Jianfeng Xu, John Kopchick, Shigeru Okada, Gary D. Meyer
-
Patent number: 8022035Abstract: Y4 receptor agonist peptide selected from the group consisting of: [Ala30]PP2-36, [Thr30]PP2-36, [Asn30]PP2-36, [Gln30]PP2-36, [Glu10]PP2-36, [Glu10,Leu17,Thr30]PP2-36, [Nle17,Nle30]PP2-36, [Glu10,Nle17,Nle30]PP2-36, their PP1-36 equivalents, and analogues and derivatives thereof as described in the specification, are selective agonists of the Y4 receptor relative to the Y1 and Y2 receptors, and are useful in the treatment, for example, of obesity and overweight, and conditions in which these are considered contributory factors, and in the treatment of diarrhoea and intestinal hypersecretion.Type: GrantFiled: September 21, 2005Date of Patent: September 20, 2011Assignee: 7TM Pharma A/SInventors: Thue Schwartz, Paul Brian Little, Lars-Ole Gerlach, Christian Elling
-
Publication number: 20110224135Abstract: The present invention relates to a (poly)peptide or a peptidomimetic thereof having the biological activity of Conkunitzin-S1, wherein said (poly)peptide is selected from (a) a polypeptide comprising or having the amino acid sequence of SEQ ID NO: 1; (b) a polypeptide having at least 85% sequence identity to SEQ ID NO:1; or (c) a fragment of a) or b); wherein said (poly)peptide or peptidomimetic specifically modulates the activity of a channel having the activity of a Kv1.7 containing channel, for the treatment or prevention of metabolic diseases or conditions, or secondary diseases or conditions related to said metabolic diseases or conditions. The present invention furthermore relates to a method of screening for (poly)peptides derived from Conkunitzin-S1 suitable for specifically modulating the activity of a channel having the activity of a Kv1.Type: ApplicationFiled: August 10, 2009Publication date: September 15, 2011Applicants: Max-Planck-Gesellschaft Zur Forderung der Wissenschaften E.V., Univesitat zu LubeckInventors: Heinrich Terlau, Rocio Finol-Urdaneta, Stefan Becker, Walter Raasch
-
Patent number: 8017573Abstract: Methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using C-terminal fragments of adiponectin receptor R1. Methods of causing the secretion of insulin in healthy and diabetic patients using C-terminal fragments of adiponectin receptor R1 are also disclosed. In addition, methods are disclosed of increasing the insulin levels in healthy patients using C-terminal fragments of adiponectin receptor R1. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed.Type: GrantFiled: July 9, 2008Date of Patent: September 13, 2011Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Michael J. Pugia, Rui Ma
-
Publication number: 20110218143Abstract: The invention generally provides compositions and methods for the repair or regeneration of a tissue or organ in need thereof.Type: ApplicationFiled: November 20, 2008Publication date: September 8, 2011Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATIONInventors: Shalesh Kaushal, Mani Annamalai
-
Publication number: 20110212882Abstract: The invention relates to methods of use of synthetic peptide amides that are ligands of the kappa opioid receptor in the treatment and prevention of kappa opioid receptor-associated diseases and conditions; and particularly to uses of these agonists in the prophylaxis, inhibition and treatment of pain, inflammation and pruritis associated with a variety of diseases, disorders and conditions. Inflammatory conditions preventable or treatable by the methods of the invention include diseases and conditions associated with elevated levels of a proinflammatory cytokines, such as TNF-?, IL-?, IL-6, MMP-1 and MMP-3.Type: ApplicationFiled: August 26, 2010Publication date: September 1, 2011Applicant: CARA THERAPEUTICS, INC.Inventors: Claudio D. Schteingart, Frédérique Menzaghi, Guangcheng Jiang, Roberta Vezza Alexander, Javier Sueiras-Diaz, Robert H. Spencer, Derek T. Chalmers, Robert Zhiyong Luo
-
Publication number: 20110212887Abstract: The present invention provides methods of treating or preventing disorders or conditions associated with enterostatin deficiency by administering to a subject in need thereof an effective amount of enterostatin. The present invention also provides methods of selecting a subject for therapy with enterostatin. Exemplary disorders or conditions associated with enterostatin deficiency include overweight, obesity, metabolic disorders, hypertension, lipid related disorders, and type II diabetes.Type: ApplicationFiled: August 18, 2010Publication date: September 1, 2011Inventors: Byron Rubin, Peter C.M. McWilliams
-
Publication number: 20110212891Abstract: The present invention relates to a compound represented by formula (I): wherein R1 represents a hydrogen atom or the like; R2 and R3 represent a hydrogen atom or the like; R4 is a group represented by (II) R5 represents a phenyl group which may be substituted with a halogen or the like; m is an integer of from 1 to 3; and p is an integer of from 0 to 4; or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 26, 2009Publication date: September 1, 2011Inventors: Osamu Okamoto, Yasuhiro Sasaki, Hitomi Watanabe, Hideki Jona, Kevin D. Dykstra
-
Publication number: 20110212883Abstract: It is an object to provide a radical scavenger, an active oxygen-scavenging agent and the like, which are highly efficacious clinically and novel, and so as to attain the object, 3,4-dihydroxyphenylalanine derivatives such as N-?-alanyl-5-S-glutathionyl-3,4-dihydroxyphenylalanine (5-S-GAD) or pharmaceutically acceptable salts thereof are contained as an active ingredient.Type: ApplicationFiled: January 7, 2011Publication date: September 1, 2011Applicant: InBiotex inc.Inventors: Shunji NATORI, Kunimiki Ootsu, Hajime Okuyama
-
Publication number: 20110212051Abstract: Novel polypeptides and polynucleotides encoding same are provided. Also provided methods and pharmaceutical compositions which can be used to treat various disorders such as cancer, immunological-related, blood-related and skin-related disorders using the polypeptides and polynucleotides of the present invention. Also provided are methods and kits for diagnosing, determining predisposition and/or prognosis of various disorders using as diagnostic markers the novel polypeptides and polynucleotides of the present invention.Type: ApplicationFiled: February 28, 2011Publication date: September 1, 2011Inventors: Michal Ayalon-Soffer, Zurit Levine, Osnat Sella-Tavor, Alex Diber, Ronen Shemesh, Amir Toporik, Galit Rotman, Sergey Nemzer, Avi Rosenberg, Dvir Dahary, Assaf Wool, Gad S. Cojocaru, Pinchas Akiva, Sarah Pollock, Kinneret Savitsky, Jeanne Bernstein
-
Publication number: 20110212138Abstract: The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance.Type: ApplicationFiled: September 4, 2009Publication date: September 1, 2011Inventors: Mary L. Houchin, Robin H. Lee, Hong Qi, Greg Oehrtman, Robert N. Jennings, Scott H. Coleman
-
Publication number: 20110207662Abstract: The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm)x-Peptide (SEQ ID NO: 76), wherein A is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidodiacetic acid group, or 4) a moiety of formula (ZyHisw)p (SEQ ID NO: 50), wherein Z is any amino acid residue other than histidine, His is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if A has alkyl group with 6 to 36 carbon units x is greater than 0; and Cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or N-Arginine or N-lysine, wherein x is an integer between 0-6 and N may be any amino acid or none. The peptide analogs are complexed with polymeric carrier to provide enhanced half-life.Type: ApplicationFiled: April 27, 2011Publication date: August 25, 2011Applicant: PharmaIN CorporationInventors: Gerardo M. Castillo, Elijah M. Bolotin
-
Publication number: 20110206745Abstract: Methods, formulations and kits are described that allow for the controlled release of octreotide, e.g., octreotide acetate, in a subject.Type: ApplicationFiled: April 29, 2011Publication date: August 25, 2011Inventors: Petr KUZMA, Stefanie Decker, Harry Quandt
-
Publication number: 20110207661Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.Type: ApplicationFiled: November 1, 2010Publication date: August 25, 2011Applicant: Theracos, Inc.Inventors: Yuanwei Chen, Huawei Cheng, Shengbin Li, Yuelin Wu, Yan Feng, Binhua Lv, Baihua Xu, Brian Seed, Michael J. Hadd, Yanli Song, Jiyan Du, Congna Wang, Jacques Y. Roberge
-
Patent number: 8003606Abstract: Described are methods of improving glycemic control/improving insulin sensitivity by administering an inhibitor of serum response factor (SRF) activity, and methods of identifying new compounds for use in the described methods of treatment.Type: GrantFiled: June 5, 2009Date of Patent: August 23, 2011Assignee: Joslin Diabetes Center, Inc.Inventors: Mary Elizabeth Patti, Wanzhu Jin, Allison B. Goldfine
-
Publication number: 20110201551Abstract: The present invention provides a composition (a blood glucose increase inhibitor) that has an effect of lowering blood glucose level in a hyperglycemic patient and that is therefore used to reduce blood glucose level in the patient. The present invention further provides a composition that is used to prevent or treat diseases caused by hyperglycemia, in particular, diabetes and diabetic complications (a composition for preventing or treating diseases caused by hyperglycemia, an antidiabetic), based on the above-mentioned effect. A feature of the present invention is using a peptide consisting of the amino acid sequence of Leu-Ser-Glu-Leu as an active ingredient.Type: ApplicationFiled: October 28, 2009Publication date: August 18, 2011Applicant: MG PHARMA INC.Inventors: Kyoichi Kagawa, Chizuko Fukuhama, Chunning Tong, Yuka Sasakawa
-
Patent number: 7998928Abstract: The present invention is based on the discovery that Humanin and humanin analogues protect pancreatic beta cells in vitro and in vivo from apoptosis. Accordingly, humanin and its analogues are useful for preventing and treating diabetes and promoting beta cell survival in a number of applications.Type: GrantFiled: September 15, 2008Date of Patent: August 16, 2011Assignee: The Regents of the University of CaliforniaInventors: Pinchas Cohen, Kuk-Wha Lee
-
Publication number: 20110192748Abstract: Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.Type: ApplicationFiled: April 21, 2011Publication date: August 11, 2011Applicant: Takeda Pharmaceutical Company LimitedInventors: Ronald J. Christopher, Paul Covington
-
Publication number: 20110195895Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.Type: ApplicationFiled: October 8, 2009Publication date: August 11, 2011Applicant: Amgen Inc.Inventors: Kenneth W. Walker, Colin V. Gegg, JR., Randy I. Hecht, Edward J. Belousky, Yue-Sheng Li, Mark L. Michaels, Jing Xu, Murielle M. Ellison
-
Publication number: 20110190195Abstract: An antioxidant compound is disclosed.Type: ApplicationFiled: April 14, 2011Publication date: August 4, 2011Applicant: Yissum Research Development Company of the Hebrew University of JerusalemInventor: Daphne ATLAS
-
Publication number: 20110190202Abstract: Preventing skin aging by targeting multiple causes by a single bullet is of primal scientific and consumer interest.Type: ApplicationFiled: April 12, 2011Publication date: August 4, 2011Applicant: ISLAND KINETICS INC.Inventors: SHYAM K. GUPTA, LINDA WALKER
-
Publication number: 20110189176Abstract: The present invention provides methods of preventing, treating or ameliorating diabetes by administering to a subject in need thereof a therapeutically effective amount of Dll4 antagonists that block Dll4-Notch signal pathways. As observed in a mouse model of diabetes, Dll4 antagonists exhibit protective effects on pancreatic islets, lower blood glucose levels, and block the production of auto-antibodies, including those against insulin and glutamic acid decarboxylase 65 (GAD65), via the expansion of regulatory T cells (Tregs). Thus, the present invention further provides methods of lowering the levels of blood glucose, and/or reducing or blocking the production of auto-antibodies, by administering to a subject in need thereof a therapeutically effective amount of Dll4 antagonists. Suitable Dll4 antagonists for the invention include antibodies or antibody fragments that specifically bind Dll4 and block Dll4-Notch interactions, the extracellular domain of Dll4, and the like.Type: ApplicationFiled: January 28, 2011Publication date: August 4, 2011Applicant: Regeneron Pharmaceuticals, Inc.Inventor: Dimitris SKOKOS
-
Publication number: 20110190201Abstract: A method, device, or kit is provided which maintain a substantially physiological cyclic pre-menopausal level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid hormones or metabolites or modulators thereof, wherein the at least one treatment regimen is determined based on pre-menopausal cyclic steroid hormone levels of the subject and on current cyclic steroid hormone levels of the subject, wherein the at least one treatment regimen is configured to maintain the subject's one or more steroid hormones or metabolites or modulators thereof at substantially physiological cyclic pre-menopausal levels. The method, device, or kit can be used for the treatment of a disease or condition in the mammalian subject.Type: ApplicationFiled: March 10, 2011Publication date: August 4, 2011Applicant: Searete LLCInventors: Roderick A. Hyde, Muriel Y. Ishikawa, Dennis J. Rivet, Elizabeth A. Sweeney, Lowell L. Wood, JR., Victoria Y.H. Wood
-
Publication number: 20110183902Abstract: Modified oxyntomodulin derivatives. Such derivatives can be used for the treatment of metabolic diseases such as diabetes and obesity.Type: ApplicationFiled: March 21, 2011Publication date: July 28, 2011Applicants: Merck Sharp & Dohme Corp., Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A.Inventors: Ranabir Sinha Roy, Elisabetta Bianchi, Antonello Pessi, Paolo Ingallinella, Donald J. Marsh, George J. Eiermann, Yingjun Mu, Yun-Ping Zhou
-
Publication number: 20110183886Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.Type: ApplicationFiled: March 29, 2011Publication date: July 28, 2011Inventors: Zheng Xin Dong, Jacques-Pierre Moreau
-
Publication number: 20110183888Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of various diseases or disorders strongly related to JNK signaling, wherein these diseases or disorders are selected from autoimmune disorders, cardiovascular diseases, cancerous diseases, diabetes, including diabetes type 1 or type 2, inflammatory diseases, hair loss, including Alopecia areata, diseases of the lung, neuronal or neurodegenerative diseases, diseases of the liver, diseases of the spine, diseases of the uterus, viral infectious diseases and depressive disorders.Type: ApplicationFiled: June 2, 2009Publication date: July 28, 2011Inventor: Christophe Bonny
-
Publication number: 20110183889Abstract: This invention pertains to the surprising discovery that salicylanilides, e.g., niclosamide and/or niclosamide analogues can be reacted with a therapeutically active peptide to produce a modified peptide complex that shows increased resistance to proteolysis and that shows higher bioactivity when orally administered than the unmodified peptide.Type: ApplicationFiled: August 28, 2008Publication date: July 28, 2011Applicant: The Regents of the University of CaliforniaInventors: Alan M. Fogelman, Mohamad Navab
-
Publication number: 20110183897Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.Type: ApplicationFiled: April 5, 2011Publication date: July 28, 2011Applicant: Amgen Inc.Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, HQ Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Patent number: 7985730Abstract: The present invention relates to 3-aminopyrrolidine derivatives of the formula I: (wherein R1, R2, R3, R4, R5, R6, R7, R8, X, Y and X are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as a modulator of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.Type: GrantFiled: April 27, 2009Date of Patent: July 26, 2011Assignee: Incyte CorporationInventors: Chu-Biao Xue, Brian W. Metcalf, Hao Feng
-
Publication number: 20110178007Abstract: The present invention relates to compounds of the general formula: (I) wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.Type: ApplicationFiled: September 30, 2009Publication date: July 21, 2011Inventors: Andrew Stamford, Michael W Miller, Duane Eugene Demong, William J Greenlee, Joseph A Kozlowski, Brian J Lavey, Michael K.C. Wong, Wensheng Yu, Xing Dai, De-Yi Yang, Guowei Zhou
-
Publication number: 20110172147Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.Type: ApplicationFiled: March 25, 2011Publication date: July 14, 2011Inventors: Karin Conde-Knape, Waleed Danho, Nader Fotouhi, David Charles Fry, Wajiha Khan, Anish Konkar, Cristina Martha Rondinone, Joseph Swistok, Jefferson Wright Tilley
-
Publication number: 20110171178Abstract: Embodiments relate to proislet peptides, preferably HIP, that exhibit increased stability and efficacy, and methods of using the same to treating a pathology associated with impaired pancreatic function, including type 1 and type 2 diabetes and symptoms thereof.Type: ApplicationFiled: August 29, 2008Publication date: July 14, 2011Applicant: CUREDM GROUP HOLDINGS, LLC.Inventors: Claresa S. Levetan, Victor M. Garsky
-
Publication number: 20110172148Abstract: A method for regenerating pancreatic tissue using recombinant periostin protein, a nucleic acid encoding said periostin and pharmaceutical compositions comprising said periostin are disclosed. Isolation of a nucleic acid encoding a periostin isoform, panc, is also taught.Type: ApplicationFiled: September 8, 2009Publication date: July 14, 2011Applicant: Ottawa Hosptial Research InstituteInventors: Michael Rudnicki, Johnathan Smid
-
Publication number: 20110166066Abstract: Circulating levels of catestatin (Cts: human chromogranin A352-372) decrease in the plasma of patients with essential hypertension. Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pre-treatment of Chga-null mice with Cts prevents blood pressure elevation, indicating a direct role of Cts in preventing hypertension. This notable vasoreactivity prompted us to test the direct cardiovascular effects and mechanisms of action of wild-type Cts (WT-Cts) and naturally occurring human variants (G364S-Cts and P370L-Cts) on myocardial and coronary functions. The cardio-inhibitory influence exerted on basal mechanical performance and the counter-regulatory action against beta-adrenergic and ET-1 stimulations, point to Cts as a novel cardiac modulator, able to protect the heart against excessive sympathochromaffin over-activation, e.g. hypertensive cardiomyopathy.Type: ApplicationFiled: May 8, 2009Publication date: July 7, 2011Inventors: Sushil Mahata, Bruno Tota, Daniel O'connor, Gautam Bandyopadhyan, Rudolf Kirchmair
-
Publication number: 20110158956Abstract: Provided is a cyclic peptide which comprises: (i) a CDK4 peptide region; and (ii) a cell-penetrating region; wherein the CDK4 peptide region comprises the amino acid sequence P1R1x1y1R2P2V (SEQ ID NO: 1), in which P1 and P2 are each proline, R1 and R2 are each arginine and each of x1 and y1 are either a linker or proline, wherein if x1 is a linker then y1 is proline or if x1 is proline then y1 is a linker, or wherein x1 and y1 when taken together form a linker, and wherein V may be present or absent; and wherein the cell-penetrating region is capable of enhancing the uptake of the cyclic peptide or a part thereof into cancer cells and comprises an amphiphilic amino acid sequence; and wherein the cyclic peptide or a part thereof is cytotoxic to and/or inhibiting to the growth of a cancer cell.Type: ApplicationFiled: March 11, 2009Publication date: June 30, 2011Applicant: THERYTE LIMITEDInventors: Hilmar Meek Warenius, William Ure Primrose
-
Publication number: 20110152181Abstract: The present invention provides Oxyntomodulin peptide analogues useful in the treatment of diabetes and/or obesity.Type: ApplicationFiled: December 15, 2010Publication date: June 23, 2011Applicant: ELI LILLY AND COMPANYInventors: Jorge ALSINA-FERNANDEZ, Wayne David KOHN
-
Publication number: 20110152183Abstract: Described are derivatives of hybrid peptides and pharmaceutical compositions comprising such, wherein said hybrid peptides comprise the C-terminal end of the human amylin peptide sequence, the middle portion of the salmon calcitonin peptide sequence and the N-terminal end of the human amylin peptide sequence, and wherein an albumin binding moiety is attached to the hybrid peptide, optionally via a linker.Type: ApplicationFiled: June 25, 2009Publication date: June 23, 2011Applicant: Novo Nordisk A/SInventors: Lauge Schäffer, Thomas Kruse
-
Publication number: 20110144012Abstract: This present invention a peptide consisting of 26 amino acids. The sequence is as follows: His-X1-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu. In comparison with the present GLP-1 and its similar compound, the shortened glucagon-like peptide 1(sGLP-1) in this invention has the following prominent advantages: 1. After reconstruction, the shortened peptide chain has stronger simulation to islet cell captors and stronger insulin secretion stimulation action; 2. the reconstructed simulation sequence can resist dipeptidyl peptidase decomposition by change of the second amino acid sequence from Ala to Gly or Ser to prolong its half time and enhance drug action; 3. To shorten the peptide chain leads to reduced synthesis cost.Type: ApplicationFiled: November 15, 2010Publication date: June 16, 2011Inventor: YUAN LI
-
Publication number: 20110142884Abstract: Provided are methods of treatment of many different diseases and disorders using micelle and sterically stabilized crystalline compounds of the invention.Type: ApplicationFiled: July 14, 2010Publication date: June 16, 2011Applicant: The Board of Trustees of the University of IllinoisInventors: Hayat Onyuksel, Israel Rubinstein
-
Publication number: 20110142850Abstract: A method for treating a CD40-mediated disease in a subject includes administering to cells expressing CD40 of the subject a therapeutically effective amount of an agent that inhibits binding of TNF receptor associated factor 2 (TRAF2) to a cytoplasmic portion of CD40.Type: ApplicationFiled: May 19, 2009Publication date: June 16, 2011Inventor: Carlos Subauste
-
Publication number: 20110144007Abstract: There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.Type: ApplicationFiled: August 7, 2009Publication date: June 16, 2011Inventor: Zheng Xin Dong
-
Publication number: 20110144008Abstract: Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and/or regulation of gastric emptying, such as diabetes and eating disorders.Type: ApplicationFiled: December 1, 2010Publication date: June 16, 2011Inventors: Bjarne Due LARSEN, Jens Damsgaard Mikkelsen, Søren Neve
-
Publication number: 20110143992Abstract: Disclosed herein are methods and compositions related to GHS-R antagonists.Type: ApplicationFiled: February 13, 2007Publication date: June 16, 2011Inventors: Dennis Taub, Vishwa Deep Dixit
-
Patent number: 7959956Abstract: The present invention relates to a method for treating diabetic complications, which comprises administering an extract obtained by: crashing and drying any one selected from Euphorbiae radix, gingered Magnolia bark, parched Puerariae radix and Glycyrrhizae radix; extracting the dried herbal material with alcohol or aqueous alcohol solution; filtering the extract; and concentrating the filtrate under reduced pressure.Type: GrantFiled: October 23, 2008Date of Patent: June 14, 2011Assignee: Korea Institute of Oriental Medicine, Ltd.Inventors: Jin Sook Kim, Sang Won Lee, Yin Mi Lee
-
Publication number: 20110136725Abstract: There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.Type: ApplicationFiled: August 7, 2009Publication date: June 9, 2011Inventor: Zheng Xin Dong
-
Publication number: 20110136724Abstract: There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.Type: ApplicationFiled: August 7, 2009Publication date: June 9, 2011Inventors: Zheng Xin Dong, Yeelana Shen, Daniel B. DeOliveira
-
Publication number: 20110136728Abstract: The present invention relates to methods of increasing bone formation in patient suffering from a wasting disorder by orally or intranasally administering a pharmaceutically effective amount of a leptin peptide and a pharmaceutically acceptable carrier, wherein the leptin peptide increases serum osteocalcin levels.Type: ApplicationFiled: December 9, 2010Publication date: June 9, 2011Inventors: Patricia Grasso, Matthew C. Leinung